Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial.

Circulation journal : official journal of the Japanese Circulation Society - 25 Jun 2020

Noda Toshiyuki, Nishigaki Kazuhiko, Minatoguchi Shinya

Abstract excerpt

BACKGROUND: Because ST-elevation myocardial infarction (STEMI) extensively damages the heart, regenerative therapy with pluripotent stem cells such as multilineage-differentiating stress enduring (Muse) cells is required. METHODS AND RESULTS: In a first-in-human study, 3 STEMI patients with a left ventricular ejection fraction (LVEF) ≤45% after successful percutaneous coronary intervention received intravenously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Lineage
Share to Myocardium

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Pluripotent Stem Cells

Share to Recovery of Function

Share to Regeneration

Share to Stroke Volume

Share to Treatment Outcome

Share to Ventricular Function, Left

Source

Identifiers

PMID: 32522904
DOI: 10.1253/circj.CJ-20-0307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial.PMID 32522904Read ↗

Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction: single-blind, multicentre, randomized controlled trialSemantic proximity Read ↗

Stem Cell Therapy for Myocardial Infarction Recovery: Advances, Challenges, and Future DirectionsSemantic proximity Read ↗

Mechanistic effects of mesenchymal and hematopoietic stem cells: New therapeutic targets in myocardial infarctionSemantic proximity Read ↗

Adult Cardiomyocyte Proliferation: a New Insight for Myocardial Infarction Therapy.Semantic proximity Read ↗

Clinical translation of mesenchymal stem cells in ischemic heart failure: Challenges and future perspectivesSemantic proximity Read ↗

Multilineage-Differentiating Stress-Enduring Cells (Muse Cells): The Future of Human and Veterinary Regenerative MedicineSemantic proximity Read ↗

Bone marrow mesenchymal stem cells induced to differentiate into cardiomyocyte-like cells and their protective effects on the heart during myocardial infarctionSemantic proximity Read ↗

Mesenchymal stromal cell therapy in ischemic heart disease.Semantic proximity Read ↗

Human embryonic stem cell-derived cardiomyocyte therapy in mouse permanent ischemia and ischemia-reperfusion modelsSemantic proximity Read ↗

Development of a potency assay for CD34+ cell-based therapy for post-acute myocardial infarctionSemantic proximity Read ↗

The Clinical Status of Stem Cell Therapy for Ischemic CardiomyopathySemantic proximity Read ↗

Effects of cardiomyopeptidin on myocardial injury in ICU patients: a prospective randomized controlled pilot studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.